Home » Stocks » FEMY

Femasys, Inc. (FEMY)

Stock Price: $9.95 USD -0.90 (-8.29%)
Updated Jun 22, 2021 4:00 PM EDT - Market closed
After-hours: $9.66 -0.29 (-2.92%) Jun 22, 4:18 PM
Market Cap 117.03M
Revenue (ttm) 1.11M
Net Income (ttm) -6.54M
Shares Out 11.76M
EPS (ttm) -0.56
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day June 22
Last Price $9.95
Previous Close $10.85
Change ($) -0.90
Change (%) -8.29%
Day's Open 11.15
Day's Range 9.71 - 11.15
Day's Volume 91,571
52-Week Range 9.71 - 13.75

News

Hide News

NEW YORK, June 21, 2021 /PRNewswire/ -- Chardan, a global investment bank, today announced that it acted as lead left bookrunner in the successful closing of the $34.45 million IPO of Femasys, Inc. (NAS...

1 day ago - PRNewsWire

Femasys Inc., a biomedical company focused on transforming women's healthcare by developing novel solutions...

5 days ago - GlobeNewswire

Femasys, Inc. has filed to go public with an IPO on the NASDAQ.

1 month ago - SEC

About FEMY

Femasys is a biomedical company focused on transforming women’s healthcare by developing novel solutions and next-generation advancements providing significant clinical impact to address severely underserved areas. As a woman-founded and led company with an expansive, internally created intellectual property portfolio with over 100 patents globally, in-house chemistry, manufacturing and controls, or CMC, and device manufacturing capabilities and proven ability to develop and commercialize products, we believe that we are well-positioned to be... [Read more...]

Industry
Surgical & Medical Instruments & Apparatus
IPO Date
Jun 18, 2021
CEO
Kathy Lee-Sepsick
Employees
24
Stock Exchange
NASDAQ
Ticker Symbol
FEMY
Full Company Profile

Financial Performance

In 2020, Femasys's revenue was $1.04 million, an increase of 11.72% compared to the previous year's $929,064. Losses were -$6.91 million, -38.65% less than in 2019.

Financial Statements